ASCO has announced a collaboration with Ryght AI aimed at accelerating the identification and activation of research sites for the CDK4/6 Inhibitor Dosing Knowledge (CDK) Study, a clinical trial evaluating different starting doses of CDK4/6 inhibitors in patients with metastatic breast cancer. The initiative seeks to shorten study startup timelines and improve patient enrollment through the use of artificial intelligence (AI)-driven site selection technology.
AI-Driven Approach to Trial Site Selection
ASCO has begun using Ryght AI’s proprietary AI Site Twin platform to analyze clinical research site data and identify centers best suited to participate in the trial. The platform assesses factors including investigator expertise, operational capacity, prior research performance, and access to appropriate patient populations. According to the organizations, the approach is designed to reduce the administrative burden and delays often associated with traditional feasibility assessments and site activation.
“Patients with metastatic breast cancer cannot afford to wait for access to clinical trials,” said Julie R. Gralow, MD, FACP, FASCO, Chief Medical Officer and Executive Vice President of ASCO. “This collaboration aims to activate the most suitable sites faster and reach more patient communities, helping us more quickly determine the most effective and tolerable doses of CDK4/6 inhibitor therapies to improve patient outcomes.”
Ryght AI’s platform maintains a continuously updated database of research capacity across clinical sites worldwide. Trial protocols are analyzed against multiple variables to generate a ranked list of potential sites. The technology also incorporates feasibility questionnaires and performance analytics and automates the assessment of historical trial performance, competing studies, regulatory history, and enrollment trends.
“Too many metastatic breast cancer trials lose precious months in slow, manual, and error-prone site selection processes,” said Chadi Nabhan, MD, MBA, FACP, Chief Medical Officer and Head of Strategy at Ryght AI. “Our mission at Ryght is to transform clinical trial timelines by giving research sponsors and networks like ASCO an AI-driven platform that quickly surfaces the right sites for the right studies.”
Addressing an Evidence Gap in Older Adults
ASCO indicated that integrating the platform into its research infrastructure will enable the organization to evaluate scalable models for AI-enabled site selection. The effort is intended to improve operational efficiency and broaden access to high-quality evidence generation in oncology, with potential future application across other cancer trials.
The CDK Study focuses on dosing strategies for oral CDK4/6 inhibitors in older adults with metastatic breast cancer. Investigators hope to address an important evidence gap related to dose optimization and individualization, particularly because older adults—especially those older than 75 years—have historically been underrepresented in CDK4/6 inhibitor clinical trials despite bearing a substantial burden of disease.
